Kingswood Wealth Advisors LLC Purchases 5,810 Shares of Astrazeneca Plc $AZN

Kingswood Wealth Advisors LLC lifted its position in shares of Astrazeneca Plc (NYSE:AZN) by 180.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 9,024 shares of the company’s stock after buying an additional 5,810 shares during the quarter. Kingswood Wealth Advisors LLC’s holdings in Astrazeneca were worth $830,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in AZN. Triumph Capital Management bought a new position in shares of Astrazeneca during the third quarter worth approximately $25,000. Bangor Savings Bank increased its stake in shares of Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares during the period. Eagle Bay Advisors LLC bought a new position in shares of Astrazeneca during the fourth quarter worth approximately $30,000. Rakuten Investment Management Inc. bought a new position in shares of Astrazeneca during the third quarter worth approximately $31,000. Finally, YANKCOM Partnership bought a new position in shares of Astrazeneca during the fourth quarter worth approximately $31,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

Astrazeneca stock opened at $189.71 on Friday. Astrazeneca Plc has a one year low of $132.32 and a one year high of $212.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. The firm has a market cap of $294.22 billion, a price-to-earnings ratio of 32.68, a P/E/G ratio of 1.45 and a beta of 0.35.

Astrazeneca Announces Dividend

The business also recently disclosed a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were paid a dividend of $1.595 per share. This represents a yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s dividend payout ratio (DPR) is 74.83%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. Citigroup assumed coverage on Astrazeneca in a research note on Tuesday, January 27th. They set a “buy” rating on the stock. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Finally, Weiss Ratings assumed coverage on Astrazeneca in a research note on Wednesday, March 11th. They set a “buy (b)” rating on the stock. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.67.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.